Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Souglakos, Ioannis
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28
Koskinas, Ioannis
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Souglakos, Ioannis
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28
Koskinas, Ioannis
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28